Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $6.4 million.

  • Puma Biotechnology's Accounts Payables fell 1495.54% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 1495.54%. This contributed to the annual value of $5.5 million for FY2024, which is 2003.19% down from last year.
  • Per Puma Biotechnology's latest filing, its Accounts Payables stood at $6.4 million for Q3 2025, which was down 1495.54% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Accounts Payables registered a high of $20.0 million during Q3 2021, and its lowest value of $5.1 million during Q3 2023.
  • Over the past 5 years, Puma Biotechnology's median Accounts Payables value was $7.8 million (recorded in 2023), while the average stood at $9.1 million.
  • Per our database at Business Quant, Puma Biotechnology's Accounts Payables tumbled by 6609.5% in 2023 and then surged by 7318.79% in 2024.
  • Over the past 5 years, Puma Biotechnology's Accounts Payables (Quarter) stood at $11.2 million in 2021, then crashed by 42.37% to $6.4 million in 2022, then rose by 6.97% to $6.9 million in 2023, then fell by 20.03% to $5.5 million in 2024, then grew by 15.92% to $6.4 million in 2025.
  • Its Accounts Payables stands at $6.4 million for Q3 2025, versus $5.4 million for Q2 2025 and $6.0 million for Q1 2025.